| Heading: |
Medicines and Healthcare Products Regulatory Agency: Costs |
| Question ID: |
1804536 |
| UIN: |
53604 |
| House: |
Commons |
| Date tabled: |
2025-05-20 |
| Asking Member ID: |
4592 |
| Asking Member display name: |
Dr Caroline Johnson
|
| Asking Member handle: |
drcarolinej
|
| Asking Member Twitter reference: |
@drcarolinej
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, with reference to the impact assessment for the Medical Devices and Blood Safety and Quality (Fees Amendment) Regulations 2025, published on 25 February 2025, whether the calculations used to estim |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-06-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) is subject to the increase in employer National Insurance contributions announced in the 2024 Autumn Budget. For their current fees uplift, the MHRA modelled their future costs, using historic... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |